Artificial jelly set to restore lost sight for people with diabetes

Brand new research launched today at the British Pharmaceutical Conference in Manchester is bringing hope to hundreds of people with diabetes who lose their sight each year as a side-effect of the disease.

People with diabetes commonly experience blindness, or a reduction in sight, when a lack of oxygen at the back of the eye causes tiny blood vessels to overgrow into the vitreous humour, which is a jelly like substance. This jelly like substance is removed during surgery to treat this problem.

Pharmaceutical researchers at the University of East Anglia have revealed that they are developing an artificial form of this vitreous humour so that it can be replaced following surgery or if it has been damaged or degenerated for other reasons.

Biologist Janine Morris working with Pharmacist Susan Barker and Biologist Julie Sanderson at the School of Chemical Sciences and Pharmacy, University of East Anglia, is identifying the essential characteristics of the human and pig vitreous humour so that they can be mimicked artificially.

She says: "I am currently making a gel that imitates the vitreous humour and which is non-cytotoxic to the human eye. The substance will also include anti-angiogenic drugs to prevent the blood vessels re-growing and the original damage re-occurring."

Placing this artificial jelly into the damaged eye should certainly improve and potentially restore lost sight. Janine Morris says that the research, which is in the preliminary stages, is good news for diabetes sufferers who will be protected against recurring damage. "The idea that we can potentially improve and maintain sight for diabetes sufferers by replacing the vitreous humour is amazing," she says.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rare variant analysis reveals genetic spectrum of monogenic diabetes genes